August 02, 2018 - Medgenics, Inc. (NASDAQ:GNMC) has filed a financial statement reporting Liabilities of $4,943,000 USD. Previously, on May 15, 2018, Medgenics, Inc. reported Liabilities of $4,739,000 USD. This represents a change of 4.30% in Liabilities.

GNMC / Aevi Genomic Medicine, Inc. Liabilities
Share on StockTwits

Embed this chart!
<a href="https://fintel.io/fg/us/gnmc/Liabilities"><img src="https://images.fintel.io/us-gnmc-liabilities.png" alt="GNMC / Aevi Genomic Medicine, Inc. Liabilities"><a>

Period EndPeriodValue
2018-06-30 2018-Q2 4,943,000
2018-03-31 2018-Q1 4,739,000
2017-12-31 2017-Q4 4,140,000
2017-09-30 2017-Q3 6,857,000
2017-06-30 2017-Q2 4,917,000
2017-03-31 2017-Q1 5,450,000
2016-12-31 2016-Q4 5,583,000
2016-09-30 2016-Q3 5,496,000
2016-06-30 2016-Q2 3,927,000
2016-03-31 2016-Q1 3,555,000
2015-12-31 2015-Q4 3,908,000
2015-09-30 2015-Q3 10,409,000
2015-06-30 2015-Q2 3,766,000
2015-03-31 2015-Q1 3,513,000
2014-12-31 2014-Q4 4,618,000
2014-09-30 2014-Q3 3,561,000
2014-06-30 2014-Q2 4,352,000
2014-03-31 2014-Q1 4,657,000
2013-12-31 2013-Q4 4,664,000
2013-09-30 2013-Q3 6,372,000
2013-06-30 2013-Q2 4,426,000
2013-03-31 2013-Q1 5,115,000
2012-12-31 2012-Q4 5,773,000
2012-09-30 2012-Q3 7,122,000
2012-06-30 2012-Q2 7,660,000
2012-03-31 2012-Q1 4,666,000
2011-12-31 2011-Q4 3,865,000
2011-09-30 2011-Q3 5,022,000
2011-06-30 2011-Q2 4,608,000
2010-12-31 2010-Q4 12,195,000

Other Interesting Charts

Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost - Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities - Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other - Financial Expenses - General And Administrative Expense - Income Tax Expense Benefit - Increase Decrease In Prepaid Deferred Expense And Other Assets - Other Finance Expense - Other Nonoperating Expense - Other Research And Development Expense - Prepaid Expense And Other Assets Current - Research And Development Expense - Research And Development Expenses Gross -

Related News Stories

Aevi Genomic Medicine (GNMX) Presents At Rodman & Renshaw.C. Wainwright 20th Annual Global Investment Conference - Slideshow

2018-09-06 seekingalpha
The following slide deck was published by Aevi Genomic Medicine, Inc. in conjunction with this event.

Evaluating KemPharm's KP415, Part 2: The History Of ADHD Treatment And The Competitive Landscape

2018-06-21 seekingalpha
KemPharm will soon publish the results of its Phase 3 clinical trial for KP415, a prodrug of dexmethylphenidate. (73-2)

Aevi Genomic Medicine: Try Subgroups Until It Works?

2018-05-20 seekingalpha
Aevi's current strategy has a reasonable chance of success, but the stock has several red flags and remains highly speculative. (20-1)